Loyal Valley Capital

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

Jinyuansheng engages in the development, smelting, and deep processing of energy metal mineral resources, lithium-ion battery cathode precursor materials, and the recycling and echeloning of power batteries and materials. They use the power of science and technology to create new materials, support energy, and create a greener world for humans.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.

Developer and provider of bio pharmaceutical products designed to create antibodies for the treatment of cancer. The company's research focuses on tumor immunotherapy antibody projects and drugs for cancer treatments, enabling patients to receive tumor and cancer medical treatment and support, improving their conditions.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Provider of a nutrition product designed to improve women's health. The company is specialized in the development of a nutrition product, "birds' net", to provide sufficient necessary nutrients to women and improve women's health and beauty conditions.

Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company has a portfolio of breakthrough technologies aimed at addressing various eye care challenges, including rare diseases through gene therapy. Established by prominent life sciences investors, Arctic Vision is led by a team of experienced professionals from the ophthalmic industry, bringing extensive expertise in research, development, and commercialization of eye care products. The company aims to deliver effective solutions not only in China but also across Asia and globally.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting oncology, metabolic diseases, and autoimmune diseases. Utilizing its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor integrates various scientific disciplines, including structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. This approach allows the company to efficiently produce both best-in-class and first-in-class therapeutic molecules. With a strong emphasis on scientific expertise, Regor Therapeutics aims to deliver clinically differentiated treatments that address unmet medical needs.

CARsgen Therapeutics, Ltd., a clinical-stage immunotherapy company, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapeutics for treating cancers. It offers CAR-T Technology that directs T cells to recognize cancer cells based on expression of specific cell surface proteins to treat solid and hematologic tumors. The company’s CAR-T cells target the GPC3 receptor for the treatment of late-stage hepatocellular carcinoma (HCC, or liver cancer) and lung squamous cell carcinoma (a common type of lung cancer). CARsgen Therapeutics, Ltd. is based in Shanghai, China.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

Sinovent Inc. is a biopharmaceutical company founded in 2016 and headquartered in Suzhou, China, with additional offices in Beijing and Boston. The company focuses on innovation in healthcare by utilizing an advanced biotechnology platform and leveraging extensive management experience and financial resources. Sinovent is dedicated to developing and promoting treatment methods to address global health challenges. Currently, the firm has 12 products in various stages of development, targeting therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. Through its commitment to research and development, Sinovent aims to provide effective medical solutions to improve patient health outcomes.

OBiO Technology is a biotechnology company specializing in gene therapy solutions. It offers contract research organization (CRO) services focused on the development of gene therapy vectors, gene function research, and drug target efficacy. The company also provides contract development and manufacturing organization (CDMO) services, which include process development, testing, and IND-CMC pharmaceutical research. Additionally, OBiO Technology supports the production of clinical samples under Good Manufacturing Practices (GMP) for genetic drug research and development. Through its comprehensive offerings, the company aims to advance the field of gene therapy and facilitate the development of innovative therapeutic solutions.

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

Hygeia Healthcare Group is a leading oncology-focused healthcare group in China. The company operates its own hospitals, provides third-party radiotherapy service, and manages partner hospitals. Its core business consists of 7 oncology hospitals and 3 managed hospitals in in 6 provinces in China. In addition, the company provides services to 15 hospital partners (including managed hospitals) in 9 provinces of China on its radiotherapy centers.

Beaver Education is an Internet education company committed to providing professional and high-quality online teaching services for elementary and middle school families as well as educational institutions. The company's products mainly include online subject training courses and online personalized tutoring tools.

Beijing Pop Mart Cultural Creative Corp., Ltd owns and operates retail stores. The company sells POP MART lifestyle commodities, including toy, home, digital, stationary, bags, accessories, beauty, and candy. It owns stores in Beijing, Tianjin, Shaanxi, Jiangsu, Liaoning, and Shanghai, China. Additionally, the company also retails the products through its web portal. Beijing Pop Mart Cultural & Creative Corp., Ltd. was founded in 2010 and is headquartered in Beijing, China.

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical company founded in 2017 and based in Shanghai, China. It specializes in the research, development, manufacturing, and sales of macromolecular drugs, including therapeutic monoclonal antibodies, vaccines, and long-acting recombinant proteins. The company's product pipeline encompasses over thirty drug varieties targeting conditions such as tumors, autoimmunity, infections, and ophthalmic diseases. Currently, six of these products are in clinical development, with three advancing to Phase III clinical trials. Mabwell has established a strong presence in the biopharmaceutical sector by integrating multiple R&D and production enterprises within the Zhangjiang Hi-Tech Park.

Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, that focuses on the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. Established in 2008, RemeGen specializes in innovative biologics, including monoclonal antibodies and antibody-drug conjugates. Its key products under development include Telitacicept, which targets autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and Disitamab Vedotin for various cancers. The company is also advancing other candidates like RC28 and RC88 for retinal conditions, alongside several pre-clinical products aimed at treating solid tumors. RemeGen operates primarily in China but also maintains laboratories and offices in Beijing and California, emphasizing its commitment to fulfilling the medical needs of patients with life-threatening conditions.

Kaishuo Jianggushi is a children's content provider. Also known as Kaishu Story, the brand is focusing on children’s stories with additional products such as audio series and online parenting courses.

Juvenile is a learning and counseling application for primary and secondary schools, mainly for 7-15 year olds. The application covers the knowledge points and exam focus of each subject in primary and secondary schools, and answers the test proposition in detail. The knowledge coverage can meet the needs of further studies, and can also help students to self-study after class. The app also provides students with effective learning method guidance, audio books and learning materials.

Akeso, Inc. is a clinical-stage biopharmaceutical company based in Zhongshan, China, focused on the discovery, development, and commercialization of innovative therapies targeting oncology, immunology, and other therapeutic areas. The company has a diverse pipeline that includes over 30 drug candidates, with 17 currently in clinical trials. Notable developments include AK104, a PD-1/CTLA-4 bi-specific antibody, and Penpulimab (AK105), a monoclonal antibody in Phase III trials for non-small cell lung cancer. Akeso also develops AK112, a PD-1/VEGF bi-specific antibody for solid tumors, alongside other candidates for severe psoriasis and autoimmune diseases. The company collaborates with various pharmaceutical partners to enhance its research and development capabilities and aims to meet global medical needs with its next-generation therapeutic antibodies.

Happy Twist, the largest drama agency in China, was founded in 2003 and has created a large amount of popular dramas, including “Clown Loves Beauty”, “Count of Mountain Wulong”, “Dream of those Years”, etc. In Oct 2015, Happy Twist’s first movie, “Xialuo’s trouble” earned nearly 1.5 billion RMB box office with 20 million RMB production cost. In Oct 2016, its second movie, “Donkey water” came into existence and achieved a high reputation. With more than 20 high quality original shows (IPs owned by the company), Happy Twist had over 1,600 tour shows across China in 2016.

Shanghai Allist Pharmaceuticals Co., Ltd. is a pharmaceutical company focused on the discovery, development, and commercialization of products aimed at improving human health. Established in 2004 and based in Shanghai, China, the company offers both generic and branded pharmaceuticals, specifically targeting treatments for cardiovascular diseases, acid-related disorders, and cancer. Allist Pharmaceuticals is recognized for its innovative approaches, particularly in the field of cancer treatment, and operates both domestically and internationally to expand its reach in the pharmaceutical market.

NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.

Juvenile is a learning and counseling application for primary and secondary schools, mainly for 7-15 year olds. The application covers the knowledge points and exam focus of each subject in primary and secondary schools, and answers the test proposition in detail. The knowledge coverage can meet the needs of further studies, and can also help students to self-study after class. The app also provides students with effective learning method guidance, audio books and learning materials.

Infinovo was formed in 2016. For the past several years, Infinovo has been focusing on developing an accurate and affordable CGM (Continuous Glucose Monitoring) for patients which will be available for both Type 1 and Type 2 Diabeties. The company has developed a CGM which can compete in the global market for accuracy, durability, and design.

EVE Energy was established in 2001 and became listed on Shenzhen GEM in 2009 as the first listed enterprise with lithium battery for principle work (stock code: 300014). As a national high-tech enterprise, EVE focuses on lithium battery innovation and manufacturing. After 33 years’ accumulation and 15 years’ endeavor, EVE now stands in the leading position of national lithium primary battery and takes front position worldwide in lithium thionyl chloride battery manufacture.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Jinfuzi is an online investment platform that offers a range of wealth management services, allowing users to invest in various financial products, including private equity, venture capital, trusts, and foreign funds. The platform is designed to assist investors in selecting investment portfolios that align with their return-risk preferences. Jinfuzi provides two primary mobile applications: Finance Port and Snowball, which facilitate access to a diversified selection of investment options. Through its comprehensive services, Jinfuzi aims to cater to the diverse needs of investors seeking to optimize their financial growth.

InnoCare Pharma Limited is a biopharmaceutical company focused on developing innovative treatments for cancer and autoimmune diseases. Founded in 2015 and headquartered in Wanchai, Hong Kong, InnoCare operates additional offices in major cities across China and in Cambridge, Massachusetts. The company is advancing several clinical programs, including Orelabrutinib, which targets various B-cell malignancies and is currently undergoing registrational trials. It is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor, and ICP-105, which targets FGFR4 in advanced hepatocellular carcinoma. InnoCare's preclinical pipeline includes promising candidates aimed at treating specific cancer types and autoimmune disorders. The firm is supported by a highly qualified scientific team and a specialized advisory board, reinforcing its commitment to pushing the boundaries of drug innovation and improving patient outcomes.

Teligene was established in 2011. It is a high-tech pharmaceutical research and development company focusing on the research and development and industrialization of small molecule innovative drugs. The company's senior technical management team is experienced and familiar with cutting-edge drug development technologies and development trends at home and abroad. The company mainly aims to research and develop hot spots and develop trends of new international small molecule targeted anti-tumor drugs, and designs, screens, optimizes and develops original small molecule targeted anti-tumor drugs with independent intellectual property rights.

Immupeutics Medical Technology Co., Ltd. is a biomedical research technology company dedicated to the development and application of tumor immunotherapy technology. The company mainly involves the research and application of immunotherapy for many different types of tumors.

ByteDance is an Internet technology company headquartered in Haidian, China, established in March 2012. The company specializes in creating mobile applications that cater to online media, entertainment, and social networking. ByteDance leverages artificial intelligence and machine learning to personalize content for users, enabling them to discover and engage with creative platforms tailored to their interests. With a robust user base of nearly 200 million daily active users, each spending an average of one hour daily on its products, ByteDance fosters connections between people and information. Its portfolio includes popular applications such as Topbuzz, Flipagram, and various user-generated content short-form video platforms, which have gained significant traction among mobile users globally. The company also maintains offices in the USA and Japan, enhancing its international presence.

Linklogis is a Chinese supply chain financing service provider that specializes in technology solutions to enhance financial operations within the supply chain. The company employs big data, artificial intelligence, and blockchain technologies to develop a platform that connects asset providers with funding sources, facilitating convenient access to financing for small-sized businesses. Linklogis operates primarily through two segments: Supply Chain Finance Technology Solutions, which includes offerings like Anchor Cloud and FI Cloud, and Emerging Solutions, which encompasses Crossborder Cloud and SME credit technology solutions. The company is dedicated to fostering the development of the financial market and contributing to economic growth by focusing on practical applications within the supply chain ecosystem.

WeShare is a Chinese financial services provider that focuses on enhancing the capabilities of consumer financial institutions. The company facilitates access to customers, risk control, and funding for these institutions. By leveraging technology and data analysis, WeShare enables both onshore and offshore institutional investors to make secure and efficient investments in China's consumer finance sector. The firm is dedicated to developing advanced fintech capabilities and aims to foster collaboration and mutual benefits with industry partners.

Teligene was established in 2011. It is a high-tech pharmaceutical research and development company focusing on the research and development and industrialization of small molecule innovative drugs. The company's senior technical management team is experienced and familiar with cutting-edge drug development technologies and development trends at home and abroad. The company mainly aims to research and develop hot spots and develop trends of new international small molecule targeted anti-tumor drugs, and designs, screens, optimizes and develops original small molecule targeted anti-tumor drugs with independent intellectual property rights.

Chaodian Culture

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, that specializes in the research, development, and commercialization of biologics, particularly in the fields of oncology and autoimmune diseases. Founded in 2010, the company offers HLX01, a monoclonal antibody biosimilar of rituximab for treating non-Hodgkin lymphoma, and is advancing several other products through regulatory reviews. Currently, Henlius has approximately 20 clinical studies underway for a diverse portfolio that includes 10 products and 8 combination therapies. The company is also involved in collaborations to develop treatments for COVID-19 and eye diseases, such as wet age-related macular degeneration. Henlius operates both domestically in China and internationally, with a focus on providing affordable and innovative biologics. It is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

Sinovent Inc. is a biopharmaceutical company founded in 2016 and headquartered in Suzhou, China, with additional offices in Beijing and Boston. The company focuses on innovation in healthcare by utilizing an advanced biotechnology platform and leveraging extensive management experience and financial resources. Sinovent is dedicated to developing and promoting treatment methods to address global health challenges. Currently, the firm has 12 products in various stages of development, targeting therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. Through its commitment to research and development, Sinovent aims to provide effective medical solutions to improve patient health outcomes.

Provider of medical technology products and services intended to serve medical niche markets. The company's products include magnetic resonance imaging compatible infusion pump iradimed, Video bronchoscopy devices, miniature capnography device, touch control device for ultrasound, oxygen therapy optimization device, tetralogy of fallot monitor and other medical devices, enabling healthcare service providers to increase efficiency of their service.

Kaishuo Jianggushi is a children's content provider. Also known as Kaishu Story, the brand is focusing on children’s stories with additional products such as audio series and online parenting courses.

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014 that specializes in gene research and the development of advanced cancer diagnostic solutions. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which are used for companion diagnostics, genetic profiling, prognosis, and monitoring of various solid tumors, including lung, colorectal, liver, and breast cancers. GeneCast provides non-invasive and precise tumor diagnoses and personalized treatment guidance, leveraging high-throughput sequencing and bioinformatics. The company collaborates with hospitals and research institutions to enhance cancer treatment and genetic testing, aiming to improve patient outcomes and quality of life. GeneCast is also focused on advancing its research and clinical trials while expanding its distribution channels.

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

Didi Chuxing is a mobile transportation platform that offers app-based transportation services. The company offers a mobile tech-based mobility option for users across, including taxi hailing, private car-hailing, Hitch (social ride-sharing), DiDi Chauffeur, DiDi Bus, DiDi Test Drive, DiDi Car Rental, and DiDi Enterprise Solutions. As a practitioner in the sharing economy initiative, DiDi is committed to working with communities and partners to solve transportation, environmental challenges, and employment problems using big data-driven deep-learning algorithms that optimize resource allocation. Bo Zhang and Wei Cheng established the company in 2012 in Beijing, Beijing.

Established in October 2013, Sugarman Media is a comprehensive film and television organization integrating film and television planning, production and distribution, post-production, entertainment marketing, and performing arts brokerage. The company's main business is the production of online dramas, and has produced two explosive works "The Hurry" and "The Best of Us". The company has the ability to continue to produce high-quality content, and will be committed to creating high-quality film and television IP through a series of plays in the future.

Phyplus Inc., founded in 2015 and based in Shanghai, China, specializes in designing high-performance, low-power communication chips. The company focuses on developing mixed-signal integrated circuits and system-on-chips tailored for Internet of Things (IoT) applications. Phyplus is particularly known for its low-power Bluetooth solutions, which emphasize minimal power consumption, high integration, and competitive price/performance ratios. Through its innovative approach, Phyplus aims to enhance the capabilities of smart terminal devices in the expanding IoT market.

Gaosi Education Group is a Chinese educational and training institution. It is a domestic extracurricular tutorial institution that provides services for middle and primary schools. Gaosi Education Group offers courses for gifted children from primary school to junior high school. It has set up personalized one-to-one teaching centers, where mathematics competitions for primary, secondary, and high schools are one of the featured courses. Gaosi currently has nearly 10,000 students and 100 full-time teachers and personnel of teaching and researching teams. The institution was founded in December 2009 and is headquartered in Gaosi Education Building, Wudaokou, Haidian District, Beijing.

Linklogis is a Chinese supply chain financing service provider that specializes in technology solutions to enhance financial operations within the supply chain. The company employs big data, artificial intelligence, and blockchain technologies to develop a platform that connects asset providers with funding sources, facilitating convenient access to financing for small-sized businesses. Linklogis operates primarily through two segments: Supply Chain Finance Technology Solutions, which includes offerings like Anchor Cloud and FI Cloud, and Emerging Solutions, which encompasses Crossborder Cloud and SME credit technology solutions. The company is dedicated to fostering the development of the financial market and contributing to economic growth by focusing on practical applications within the supply chain ecosystem.

Rishiji (Daily Food Diary) is a popular short video producer spreading aesthetic food-cooking videos centered on its core IP. Total video views of “Rishiji” exceeded 1.3B, and average views per article reached 300K. It simultaneously operates an e-commerce business with its own brand and content-related inventory SKU.

Pipilu is a provider of entertainment content and products intended for children.

Pengding Holdings is a developer of printed circuit boards.

Established in 2013, Studio 9 is a leading original animation IP creation company. It has the highest-yield production line of comics and 2D & 3D animation in China. The company has built its IP production committee to further expand the value of its IP in animation, movies and games. It has also successfully created China's first action animation IP " The Outcast ", and hot IPs such as “No”, “Heaven to Earth”, etc.

Yanxue.com is the first online teaching platform for the internal business incubator.

Xinshixiang is a well-known brand in the content field which has extended from textual content manufacturing to famous events. The company's platform provides contents including personalized recommendation, emotional companionship, value puzzlement solutions, enabling the young generation to achieve self-worth through reading.

ECNUAS is located in Jiading District, Shanghai. ECNUAS is an international private boarding school from kindergarten to high school. The school's goal is to create a Chinese school that affects the world.

iDreamsky is a Shenzhen, China based company founded in 2009. Even since it has established to be one of the leading smartphone application developers in China. With major clients such as Lenovo, China Telecom, Chung Hwa Telecom, HTC and many more. At 2011, iDreamsky have successfully secure a 2 million USD seed investment from Hwa Xiu Investment Group to create a new business operation: Skynet a one stop solution for game developer to expand and establish their business in China.

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and commercialization of drugs targeting various therapeutic areas, including oncology, metabolic diseases, auto-immunity, and neurological disorders. The company offers a range of products, including JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR, which is indicated for multiple cancers such as melanoma and non-small cell lung carcinoma. Currently, Junshi is advancing several candidates through clinical trials, including UBP1211, a biosimilar of Humira for rheumatoid arthritis; JS002, an anti-PCSK9 monoclonal antibody for hyperlipidemia; and JS003, an anti-PD-L1 monoclonal antibody. The company has established collaborations with major pharmaceutical firms, including Eli Lilly and Merck, to develop therapeutic antibodies and explore combination treatments for various conditions. Founded in 2012, Junshi Biosciences is committed to innovation in biopharmaceuticals and aims to address significant unmet medical needs.

China Mercy Health Group was initiated and established by Liu Xiaocheng of TEDA International Cardiovascular Hospital. Dean Liu Xiaocheng has served as the vice president, principal and party committee secretary of the Chinese Academy of Medical Sciences and China Union Medical University. In 2001, Dean Liu went to Tianjin Development Zone to prepare to build TEDA International Cardiovascular Hospital. TEDA International Cardiovascular Hospital is now included in the Grade A Class A Cardiovascular Specialized Hospital and Institute of Cardiovascular Research of the Management System of Peking Union Medical College of Chinese Academy of Medical Sciences , Is the Tianjin Medical University School of Cardiovascular Diseases, National Coronary Heart Disease and Arrhythmia Intervention Diagnosis and Training Training Base.

Sound Solutions, a subsidiary of [Dover Corporation](/organization/dover)'s Knowles Electronics and formerly owned by [NXP](/organization/nxp), manufactures speakers and receivers for cell phones and other electronic devices.

Linklogis is a Chinese supply chain financing service provider that specializes in technology solutions to enhance financial operations within the supply chain. The company employs big data, artificial intelligence, and blockchain technologies to develop a platform that connects asset providers with funding sources, facilitating convenient access to financing for small-sized businesses. Linklogis operates primarily through two segments: Supply Chain Finance Technology Solutions, which includes offerings like Anchor Cloud and FI Cloud, and Emerging Solutions, which encompasses Crossborder Cloud and SME credit technology solutions. The company is dedicated to fostering the development of the financial market and contributing to economic growth by focusing on practical applications within the supply chain ecosystem.

Bilibili Inc. is an online entertainment platform based in Shanghai, China, catering primarily to the younger generation. Founded in 2009, the company has evolved from a niche content community focused on anime, comics, and games (ACG) into a comprehensive entertainment hub that offers a diverse range of media formats, including videos, live broadcasts, and mobile games. Bilibili emphasizes high-quality content and aims to create immersive experiences that foster strong emotional connections among its users. The platform features a unique interactive playback system that allows for real-time subtitle overlays, enhancing user engagement. Additionally, Bilibili has established a strategic collaboration with Tencent for the sharing and operation of anime and games, further expanding its content offerings and reach within the Chinese market.